Brentuximab vedotin monotherapy for CD30+ MF/cutaneous ALCL (1.8 mg/kg IV q3 weeks)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Components | DRUG-BRENTUXIMAB-VEDOTIN |
|---|
| ID | REG-BV-MONO-MF |
|---|---|
| Type | Regimen |
| Status | reviewed 2026-04-25 | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-NCCN-BCELL-2025 |
Notes
ALCANZA trial (Prince 2017, Lancet): brentuximab vedotin monotherapy vs methotrexate or bexarotene in CD30+ CTCL — superior ORR4 (66.7% vs 16.7%). NCCN cat 1 for CD30+ MF (≥10% by IHC) and primary cutaneous ALCL. Different from CHP-Bv (combination chemo backbone) — this is single-agent for cutaneous-predominant disease without systemic chemo intensity.
Used By
Indication
IND-MF-ADVANCED-1L-BV- IND-MF-ADVANCED-1L-BV
Monitoring
MON-MF-SYSTEMIC- MON-MF-SYSTEMIC